Project MiCRIM- Sleep and Stress Intervention

Sponsor
Florida State University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05384067
Collaborator
(none)
50
1
2
11
4.6

Study Details

Study Description

Brief Summary

The purpose of Project MiCRIM is to test the feasibility and effectiveness of an online 4-week mindfulness-based intervention that incorporates informational elements about sleep, mindfulness, thoughts, emotions, and acceptance using a control sample of Criminology and Criminal Justice majors as a proxy for Corrections officers.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness-based intervention
N/A

Detailed Description

The study will use a waitlist-control design to examine the effectiveness of a brief (4-week) online mindfulness-based intervention aimed at reducing stress and improving sleep quality. A proxy, convenience sample of 50 criminology majors will be recruited and randomized into the active intervention or waitlist condition. The intervention requires participants to complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep. Validated self-report measures of stress, anxiety, mood, and sleep quality will be assessed pre- and post-intervention. Adherence to the mindfulness practice will be monitored online and self-report assessments of sleep technique implementation will be collected. Sleep patterns will be assessed using a Philips Respironics Spectrum 2 Actiwatch, which is a wrist-worn device that measures movement and light exposure and estimates sleep-wake patterns. Lastly, multiple saliva samples pre- and post-intervention will be collected and analyzed by ELISA with a multiplex cytokine assay. Cortisol, α-amylase, and the four analytes with known deleterious roles in cellular and behavioral stress responsiveness will be measured simultaneously: interleukin-1beta, interleukin-6, interleukin-8, and Tumour Necrosis Factor-alpha will be examined pre- and post-intervention.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Intervention and control groupIntervention and control group
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Defining Stress and Sleep as Modifiable Intervention Targets in Correctional Officers to Reduce Mental and Physical Health Risk
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Mar 31, 2023
Anticipated Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness-based intervention

Participants in this arm will wear a sleep-monitoring device, complete questionnaires and participate in an online mindfulness component each week for the duration of this study.

Behavioral: Mindfulness-based intervention
Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.

No Intervention: Control

Participants in this arm will only wear a sleep-monitoring device and complete questionnaires.

Outcome Measures

Primary Outcome Measures

  1. Saliva Samples via ELISA Assay- Cortisol [Change from baseline to 5 weeks]

    Tests for level changes in cortisol.

  2. Saliva Samples via ELISA Assay- α-amylase [Change from baseline to 5 weeks]

    Test for level changes in α-amylase.

  3. Saliva Samples via ELISA Assay- interleukin-1beta [Change from baseline to 5 weeks]

    Test for level changes in interleukin-1beta.

  4. Saliva Samples via ELISA Assay- interleukin-6 [Change from baseline to 5 weeks]

    Test for level changes in interleukin-6.

  5. Saliva Samples via ELISA Assay- interleukin-8 [Change from baseline to 5 weeks]

    Test for level changes in interleukin-8.

  6. Saliva Samples via ELISA Assay- TNF-α [Change from baseline to 5 weeks]

    Test for level changes in TNF-α.

Secondary Outcome Measures

  1. Pittsburgh Sleep Quality Index (PSQI) [Change from baseline to 5 weeks]

    Assesses sleep quality. The PSQI includes a scoring key for calculating a patient's seven sub scores, each of which can range from 0 to 3. The sub scores are tallied, yielding a "global" score that can range from 0 to 21. A global score of 5 or more indicates poor sleep quality; the higher the score, the worse the quality.

  2. Pittsburgh Sleep Quality Index, Addendum for PTSD (PSQI-A) [Change from baseline to 5 weeks]

    Assesses sleep quality related to PTSD. The PSQI-A includes a scoring key for calculating a patient's scores, each of which can range from 0 to 3 with higher scores indicating worse outcomes.

  3. The Smith Relaxation Dispositions Inventory [Change from baseline to 5 weeks]

    Assesses momentary states of relaxation during the past two weeks. Items scored on a 4-point Likert Type scale ranging from 1 (not at all) to 4 (very much).

  4. Five Facet Mindfulness Questionnaire - Short Form [Change from baseline to 5 weeks]

    Assesses 5 facets of mindfulness- observation, description, awareness of actions, non-judgement and non-reaction. Items scored on a 5-point Likert-type scale ranging from 1 (never or very rarely true) to 5 (very often or always true). Facet scores were computed by summing the scores on the individual items. Facet scores range from 8 to 40 (except for the nonreactivity facet, which ranges from 7 to 35), with higher scores indicating more mindfulness.

  5. Patient Health Questionnaire 9 [Change from baseline to 5 weeks]

    Measures depression severity. This is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 0- not at all, 1- several days, 2- more than half the days, 3- nearly every day, respectively. The total score for the nine items ranges from 0 to 27. 1-4 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, 20-27 severe depression.

  6. Generalized Anxiety Disorder 7 [Change from baseline to 5 weeks]

    Assesses anxiety symptoms. Each item is scored on a four-point Likert scale (0-3) with total scores ranging from 0 to 21 with higher scores reflecting greater anxiety severity. Scores above 10 are considered to be in the clinical range.

  7. Perceived Stress Scale [Change from baseline to 5 weeks]

    Assesses perceptions of stress. Scores are obtained by reversing the scores on the four positive items, e.g., 0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4,5, 7, and 8 are the positively stated items.

  8. Sleep Condition Indicator [Change from baseline to 5 weeks]

    Eight-item rating scale that was developed to screen for insomnia disorder based on DSM-5 criteria.

  9. The PTSD Checklist for DSM-5 (PCL-5) [Change from baseline to 5 weeks]

    Assesses the 20 Diagnostic Statistical Manual-5 symptoms of PTSD using a 5-point Likert-type scale ranging from 0 (not at all) to 4 (extremely).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 24 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

-Criminal Justice or Criminology major

Exclusion Criteria:
  • Abnormal BMI (below 18.5 or above 30)

  • self-reported sleep apnea, head injury, neurological problem, unstable mental health disorder, substance use disorder, psychosis, or current suicidal ideation or plan

Contacts and Locations

Locations

Site City State Country Postal Code
1 Florida State University Center for Translational Behavioral Medicine Tallahassee Florida United States 32310

Sponsors and Collaborators

  • Florida State University

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Scott Pickett, Associate Professor, Florida State University
ClinicalTrials.gov Identifier:
NCT05384067
Other Study ID Numbers:
  • STUDY00002715
First Posted:
May 20, 2022
Last Update Posted:
Aug 18, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Scott Pickett, Associate Professor, Florida State University

Study Results

No Results Posted as of Aug 18, 2022